Q's top three insider shareholders as of August 04, 2026 are Paul Rivard (Chief Legal Officer, 400.00K shares), Chelsea Sierra Voss (Director, 239.90K shares), Bruce Bernstein (Director, 25.00K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Paul Rivard | Chief Legal Officer | 400,000 | 0 | 400,000 | 56.0% | 24 Aug, 2023 |
| 2 | Chelsea Sierra Voss | Director | 239,900 | 0 | 239,900 | 33.6% | 30 Jan, 2026 |
| 3 | Bruce Bernstein | Director | 25,000 | 0 | 25,000 | 3.5% | 14 Nov, 2025 |
| 4 | Stephen Friscia | Director | 25,000 | 0 | 25,000 | 3.5% | 14 Nov, 2025 |
| 5 | Gary M Rauch | Other | 12,500 | 0 | 12,500 | 1.7% | 14 Nov, 2025 |
| 6 | Mitchell Glass | Director, Chief Medical Off. | 12,500 | 0 | 12,500 | 1.7% | 17 Nov, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 13 Apr, 2026 | Billy Joe White | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Bruce Bernstein | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Mitchell Glass | Chief Medical Officer | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Chelsea Sierra Voss | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 212,500 | $0.00 | $0 | 214,900 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 25,000 | $0.00 | $0 | 239,900 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 212,500 | $0.00 | $0 | 212,500 | Direct |
| 04 Sep, 2025 | Biotech, Inc. Pharmacyte | TenPercentOwner | Acquired P | 889,865 | — | — | 889,865 | Direct |
| 14 Nov, 2025 | Biotech, Inc. Pharmacyte | TenPercentOwner | Acquired P | 889,865 | — | — | 889,865 | Direct |
| 14 Nov, 2025 | Mitchell Glass | Director, Chief Medical Off. | Acquired A | 11,420 | $0.00 | $0 | 12,500 | Direct |
| 14 Nov, 2025 | Gary M Rauch | Other | Acquired A | 11,420 | $0.00 | $0 | 12,500 | Direct |
| 14 Nov, 2025 | Stephen Friscia | Director | Acquired A | 22,839 | $0.00 | $0 | 25,000 | Direct |
| 14 Nov, 2025 | Bruce Bernstein | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 03 Oct, 2025 | Stephen Friscia | Director | Acquired A | 2,161 | $0.00 | $0 | 2,161 | Direct |
| 03 Oct, 2025 | Gary M Rauch | Other | Acquired A | 1,080 | $0.00 | $0 | 1,080 | Direct |
| 03 Oct, 2025 | Mitchell Glass | Director, Chief Medical Off. | Acquired A | 1,080 | $0.00 | $0 | 1,080 | Direct |
| 17 Apr, 2025 | Mitchell Glass | President, Cmo | Acquired A | 125,000 | $0.00 | $0 | 125,000 | Direct |
| 17 Apr, 2025 | Gary M Rauch | Other | Acquired A | 75,000 | $0.00 | $0 | 75,000 | Direct |
| 17 Apr, 2025 | Ian Rhodes | Interim Cfo | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 24 Aug, 2023 | Paul Rivard | Chief Legal Officer | Acquired P | 150,000 | $1.11 | $166.50K | 400,000 | Direct |